

Red Cell Exchange

September 2024 – Cambridge Symposium

Bridget Audsley

TAS - Senior Nurse Manager Education

Expert Apheresis Education

Therapeutic Apheresis Services



Blood and Transplant

8 Main units and 2 spoke units

2024 – 2 new units planned:

- Cambridge
- Middlesbrough

Staff:

~ 150 in total

~ 120 clinical staff

Including:

Education team

Governance team

trainee ACP's

Student Nurse Associates





Expert Apheresis Education



Around 20% of all procedures in 2023/24 were red cell exchange

RCX Procedures and Patients



Sickle Cell Disorder Prevalence



Affects 1 in every 2000 live births



2016/17 the NHS screening for SCD and thalassaemia identified

- 274 babies with SCD
- 8530 babies with sickle trait



12 500 – 15 000 people with SCD

50–90% of children die before the age of 5 years


Africa

Childhood mortality is rare with 99% of children surviving to adulthood

UK



Relevant Red Cell Disorders



HAEMOGLOBINOPATHY SCREEN


HPLC Screen	HPLC Screen shows Hb A + S + F	
%A	17	%
%S	79	%
%F	* 4	%

Hgb'opathy Screen interpret.


Haemoglobinopathies

<input type="checkbox"/> Haemoglobin A2	DELETED
<input type="checkbox"/> Haemoglobin F	0.6 %
<input type="checkbox"/> Haemoglobin A	L 36.8 %
<input type="checkbox"/> Haemoglobin S	25.5 %
<input type="checkbox"/> Haemoglobin C	25.0 %




Pathophysiology of sickle crises



Triggers



Treatment Options



NICE Guidelines



Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease

Medical technology guidance
Published: 2 March 2016
[nice.org.uk/guidance/mtg28](https://www.nice.org.uk/guidance/mtg28)

NICE published recommendations in March 2016 around automated red cell exchange (Reviewed in Aug 2020)

This was followed by:

Do Not Do Recommendation

Top-up transfusion is not generally suitable as a long-term regime for sickle cell disease because it is iron positive.

Do Not Do Recommendation Details

Recommendation: Top-up transfusion is not generally suitable as a long-term regime for sickle cell disease because it is iron positive.


Interventions: Top-up transfusion

American Society for Apheresis (ASFA)

Disease Name	Therapeutic Apheresis Modality	Disease Condition	Category	Grade
Sickle cell disease, acute	RBC exchange	Acute stroke	I	1C
		Acute chest syndrome, severe	II	1C
		Other Complications*	III	2C
Sickle cell disease, non-acute	RBC exchange	Stroke prophylaxis	I	1A
		Vaso-occlusive pain crisis	II	2B
		Pregnancy	II	2B
		Pre-op management	III	2A




AUTOMATED RED CELL EXCHANGE



2.10 Regular exchange transfusions are considered to be the best options for patients at high risk of vaso-occlusive events because, unlike top up transfusion, they do not increase blood viscosity. High risk patients include those who have had recurrent hospitalisations because of disease complications such as secondary stroke, painful crises, acute chest syndrome and priapism.

Red Cell Exchange: Patient Pathway



Transfusion Requirements



Optia - Programming

Height and weight and the % of Red cells in their full blood count


Pre treatment sickle level and target sickle level

Level of patients own RBC to remain

Volume of donor RBC needed



How Red Cell Exchange works...



PSYCHOSOCIAL IMPACT



Support for Red Cell Exchange



Blood and Transplant



The NHS Long Term Plan: Med Tech Funding Mandate launched 2021

Therapeutic Apheresis Services

- Development of standardised procedural guidelines
- Data collection and analysis
- Introduction of Ultrasound guided cannulation
 - 25% of staff are now trained
 - In 2023/24 – over 100 lines prevented



Expert Apheresis Education


Caring Expert Quality

Patient Experience



Blood and Transplant

[Leeds patient meeting donor](#)



Expert Apheresis Education

References

- Al-Salem, A (2016). *Medical and surgical complications of sickle cell anemia*. London: Springer
- Fuente, Josu de la, Gluckman, E, Makani, J, Telfer, P, Faulkner, L, Corbacioglu, S (2020). The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. *Lancet Haematol*; 7: e902–11
- National Institute for Health and Care Excellence [NICE] (2021). Sickle cell disease: managing acute painful episodes in hospital
- National Institute for Health and Care Excellence [NICE] (2021). Crizanlizumab for preventing sickle cell crises in sickle cell disease
- National Institute for Health and Care Excellence [NICE] (2021). Sickle Cell Disease
- Piga, A (2017). Impact of bone disease and pain in thalassemia. Hematology American Society Hematology Educational program (1), pp. 271 – 277
- RCN (2023). UK career framework for pain nurses (levels 1 to 8). London: RCN.
- ASFA Guidelines - <https://www.apheresis.org/page/Guidelines>
- NHS England MedTech Funding Mandate (2021) - <https://www.england.nhs.uk/aac/what-we-do/how-can-the-aac-help-me/the-medtech-funding-mandate/>